Why did CuraTeQ Biologics terminate its license agreement with BioFactura Inc.?

CuraTeQ terminated the agreement following a strategic review and to prioritize its product pipeline.

When will the termination of the BFI-751 biosimilar deal become effective?

The termination of the license agreement between CuraTeQ and BioFactura is effective December 27, 2025.

Will this termination affect Aurobindo Pharma's overall biosimilars strategy?

Aurobindo Pharma clarified that the termination is not expected to have any material impact on its broader biosimilars strategy.

Home / Business and Economy / CuraTeQ and BioFactura End Stelara Biosimilar Pact

CuraTeQ and BioFactura End Stelara Biosimilar Pact

27 Dec

•

Summary

CuraTeQ, Aurobindo subsidiary, terminates BioFactura license agreement.
The termination of the biosimilar deal is effective December 27, 2025.
Decision follows a strategic review and pipeline prioritisation by CuraTeQ.

CuraTeQ and BioFactura End Stelara Biosimilar Pact

CuraTeQ Biologics Private Limited, a subsidiary of Aurobindo Pharma Limited, has mutually agreed to end its license agreement with BioFactura Inc. This agreement was for the commercialization of BFI-751, a proposed biosimilar of ustekinumab, commonly known as Stelara. The decision to terminate the pact, which was initially established in July 2023, stems from a strategic review and CuraTeQ's ongoing efforts to prioritize its product pipeline. Under the original terms, BioFactura was to receive development and commercial milestone-linked license fees, while CuraTeQ held global manufacturing rights with a profit-sharing arrangement. This termination, effective December 27, 2025, is expected to have no significant impact on Aurobindo Pharma's overall biosimilars strategy or its long-term growth plans. The company emphasized that BioFactura is not related to its promoters, ensuring the transaction is not a related-party dealing. CuraTeQ remains focused on optimizing its biosimilars pipeline.